Novartis today announced that nearly 170 abstracts highlighting investigational uses of current therapies and investigational agents in the Novartis Oncology portfolio will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) from June 4 through June 8 in Chicago, IL.
These data include results with Tasigna (nilotinib), Zometa (zoledronic acid), Afinitor (everolimus) tablets, panobinostat (LBH589) and targeted pipeline therapies that underscore the Company’s dedication to improving treatment for cancer patients around the world by developing therapies based on the molecular pathways of various cancers and tumor types.
“Our scientific presence at ASCO speaks to our commitment to improve cancer treatment by discovering, developing and making available individualized therapies for diseases where there is unmet medical need,” said Herve Hoppenot, President, Novartis Oncology. “Through our robust discovery and development program, we will continue to be a leader in the oncology community,working to bring forth significant treatment advances that strive to improve the lives of patients suffering from cancer.”
For more information, please click the link below: